)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Molecure
Molecure (MOC) investor relations material
Molecure Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary30 Sep, 2026
Executive summary
Focus on R&D of small-molecule drugs for high unmet clinical needs, especially oncology and respiratory diseases.
Financial statements cover the six months ended June 30, 2026, with comparative data for 2025.
Company remains in the R&D phase, incurring significant development costs before commercialization.
Cash and equivalents at June 30, 2026, totaled PLN 24.9 million.
Additional financing will be required in Q1 2027 to maintain planned R&D activities.
Financial highlights
Operating revenue for H1 2026: PLN 1.86 million, down from PLN 3.52 million in H1 2025.
Operating loss: PLN -6.34 million (H1 2026) vs. PLN -9.13 million (H1 2025).
Net loss: PLN -6.31 million (H1 2026) vs. PLN -8.52 million (H1 2025).
Net cash from operating activities: PLN -1.39 million (H1 2026) vs. PLN -10.64 million (H1 2025).
Net cash from financing activities: PLN 20.6 million (H1 2026), mainly from share issuance.
Total assets at June 30, 2026: PLN 112.6 million; equity: PLN 101.3 million.
Basic and diluted loss per share: PLN -0.29 (H1 2026) vs. PLN -0.41 (H1 2025).
Outlook and guidance
Management expects the need for additional funding in Q1 2027 to continue R&D programs.
Ongoing efforts to secure capital through equity or partnering transactions.
Flexibility to adjust R&D timelines and expenditures if needed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Molecure
- OATD-01 advances in clinical trials with strong market potential and active partnering discussions.MOC
Investor presentation - Clinical and financial progress continues, with focus on partnerships and accelerated enrollment.MOCQ4 2024
- Q1 2026: Clinical milestones, cost cuts, PLN 20m raised, net loss narrows to PLN -4.06m.MOCQ1 2026
- Improved financials and clinical progress in 2025 set the stage for key partnering in 2026.MOCQ4 2025
- Net loss narrowed to PLN -14.0m as clinical programs advanced and cost base was reduced.MOCQ3 2025
- Net loss narrowed to PLN 8.52 million in H1 2025, with strong cash reserves and cost optimization.MOCQ2 2025
- Net loss of PLN 14.6 million in H1 2024, with robust equity and ongoing R&D investment.MOCQ2 2024
- Net loss deepened to PLN 20.83m as Molecure advanced clinical and mRNA drug programs.MOCQ3 2024
- OATD-01 and OATD-02 drive Molecure's growth, targeting major unmet needs in inflammation and cancer.MOCInvestor Presentation
Next Molecure earnings date
Q3 202630 Oct, 2026
Molecure
Next Molecure earnings date
Q3 202630 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage